

TABLE OF CONTENTS

June 7, 2010

No. 2191

BUSINESS

- 1 Sanofi-aventis Aims at Top-5 Position in 5 Years in Japan: CEO C. Viehbacher
 - Entering Generics Market by Creating Joint Venture with Nichi-Iko
 - Deal Benefits Both Sanofi-aventis and Nichi-Iko
 - Gov't, Industry Welcome Entry of Mega Pharmas
- 3 Daiichi Sankyo to Insist on Achieving Numerical Goals: New President Nakayama
- 4 Astellas Aims at Sales of ¥1,100 Bil. in FY2014
 - Making Oncology 3rd Most Important Therapeutic Area
 - No. of MRs to Be Increased in the US, China
- 5 Teijin Pharma to Increase No. of MRs to Market TMX-67
 - Enhancing Clinical Development Capability in China
 - Seeking Alliances to Reduce Promotion Costs for Off-Patent Products
 - Sales Up 3.6% to ¥131.7 Bil. for Pharm./Home Health Care
 - Aiming to Launch Febuxostat by Fall 2011 in Japan
- 6 Takeda Aims at Top Share for DPP-4 Inhibitors with Nesina
- 7 Mark Smith Appointed President of Merck Serono in Japan
- 7 **Statistics**
 - Ethical Drugs' Sales Up 4.7% in FY2009: Crecon
- 8 Average Operating Profit Rate Up to 0.57% for Top-4 Wholesalers
- 9 Toho Aims at Reducing *Yakkasa* by 1.5-2 Points
 - Toho Achieves Nationwide Presence by Acquiring an Okinawa-Based Company
- 10 Zeria Aims at Overseas Sales Ratio of >25%: President Ibe
 - Asacol Props Up Sales
- 10 **Business Results for FY2009**
 - Meiji Seika: Pharm. Business Driven by Generics
 - Ajinomoto: Pharm. Sales Down 3.7% to ¥82.6 Bil.
 - Asahi Kasei Pharma: Sales Down 8.2% to ¥56.0 Bil.
 - Yakult: Campto Patent Expiration Hits Pharm. Business
 - Fuso: Pharm. Sales Up 1.5% Driven by Dialysis-Related Products
 - ASKA: Large Drop in Profits Despite 17.6% Increase in Sales
 - Seikagaku: Artz Props Up Sales 1.5% to ¥27,617 Mil.
 - Wakamoto: Sales Down 3.0% to ¥9,776 Mil.
 - JCR Pharmaceuticals: Sales Up 19.1% to ¥14,387 Mil.

14 BUSINESS NEWS IN BRIEF

- Astellas, NBI Extend Marketing Agreement for Micardis
- NanoCarrier Obtains Substance Patent Related to Polymer Micelles
- Eisai Opens New Oncology Drug Production Facility in the US
- Finished Drug Products Show Largest Production in 10 Years in FY2008
- Market for Hypotensives to Expand to ¥1 Tril. in 2018: Fuji-Keizai

GENERICS

- 16 5 APIs See 1st Generics Listed
- 17 Incentives for Use of Generics Boost Business of JGA Member Companies
 - Sales Volume-Based Share Up Slightly to 17.6% in FY2008
- 18 **NEW PRODUCTS**
 - Japan's 1st Biosimilar EPO Launched by Kissei, JCR
- 19 Major New Entrants in Generics Market, Emergence of AGs: Part 2
- 18 **Survey**
 - Women Receives Cervarix at 31.4 of Age on Average in Japan: GSK

REGULATORY

- 22 Revlimid, Torisel Recommended for Approval
- 23 Industry Should Generate Visible Benefits of New Premium System: Dr Suzuki of JMA

MEDICAL DEVICES

- 24 AZ, J&J to Jointly Develop CAPS System in Japan
- 24 Takara Bio: Sales Up 2.2% to ¥19,325 Mil.
 - Aiming at Sales of ¥21.5 Bil. in FY2012

25 OPINION

- A Coming of Age: Philip Carrigan

R&D

- 26 *Korosho* Asks Companies to Develop 108 Drugs & Indications
- 26 **R&D NEWS IN BRIEF**
 - Otsuka Discontinues Development of Amsilarotene
 - Favorable PII Results Obtained with Riociguat for Pulmonary Hypertension
 - Sanofi-aventis Begins Large-Scale Study with Multaq in Permanent AF

MEDICAL FACILITIES & NURSING CARE

- 27 New GL for Osteoporosis to Reflect Results of JOINT-02 Study